23andMe IPO

23andme.com | Healthcare/Biotech | Founded: 2006 | Funding to Date: $791,607,056

23andMe, founded in April 2006 by Linda Avey, Paul Cusenza, and Anne Wojcicki. The company has not officially endorsed a plan to participate in an IPO.

23andMe provides at-home, consumer genetic testing and was the first FDA-approved direct-to-consumer genetic sequencing supplier. More recently, 23andMe has leveraged its genetic database in pursuit of pharmaceutical drug development. The company has raised nearly $800 million in Venture Capital funding from investors including GlaxoSmithKline, Pegasus Tech Ventures, MicroVentures, G Squared, Sapphire Ventures, Sequoia Capital, SharesPost, Fidelity, GV, and Genetech. It has been widely reported that 23andMe last raised $300 million in July 2018 at a post-money valuation of $2.5 billion.

Date of Last Funding Round July 2018
Value at Last Round $2.51 B
Amount of Last Raise $300 MM
Total Funding to Date $791.61 MM

ENTERPRISE VALUE (based on primary fundings)

To see more on key investors in 23andMe, please register or login >>

Mutual Funds holding 23andMe

  • Fidelity Advisor New Insights Fund - December 2018

  • Fidelity Contrafund - December 2018

  • Fidelity Contrafund K6 - December 2018

To see more, including pricing data for each fund, please register or login >>

Learn more about buying or selling 23andMe Stock >>



DNA tests were a big holiday hit — in 2018. This past year, Ancestry and 23andMe DNA kit sales on their websites saw major declines, according to new data. As a result, both 23andMe and Ancestry have recently had major layoffs.


None of the information displayed on this page (i) represents an offer to buy or sell or a solicitation of an offer to buy or sell any security, (ii) constitutes an offer to provide investment advice or service, nor (iii) should be construed to mean that a company has officially endorsed a plan to participate in, or forego, an IPO merely by its inclusion on this page.